Abstract. LY573636-sodium is a promising anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo. Moreover, studies have shown that the compound is selectively toxic towards tumor cells over their normal counterparts. This targeted effect makes LY573636 a candidate for combined therapy regimens in patients with advanced or resistant cancers. We studied for the first time, the anti-tumor properties of LY573636 against a variety of human hematopoietic malignancies, including AML, B-ALL, large B-cell and mantle cell lymphoma cell lines. Cells were treated with the compound in vitro and its effect on cell proliferation, apoptosis and differentiation was determined. The cell lines underwent growth arrest in response to treatment with LY573636 in a dose-dependent manner. This antiproliferative activity was associated with the induction of apoptosis, loss of mitochondrial membrane potential and induction of reactive oxygen species. Furthermore, we showed that LY573636 was able to induce granulocytic/monocytic differentiation of HL60 and U937 cells. LY573636, as shown before in solid tumors, is effective in hematopoietic cell lines as well. These data suggest the use of LY573636 alone or in combination with conventional chemotherapeutic regimens in hematopoietic malignancies.
Introduction
LY573636-sodium (hereafter referred to as LY573636), a benzamide, N-[(5-bromo-2-thienyl)sulfonyl]-2,4-dichlorosodium salt, was initially identified for its selective activity against solid tumors using an in vitro soft agar disk diffusion assay. This compound has demonstrated significant dosedependent antitumor activity against xenograft models of HCT116 and SW620 human colon cancers, as well as A375 melanoma (1; Lilly Research Laboratories, LRL, unpublished data). Other acyl sulfonamide analogues identified during the development of LY573636 have been reported in recent years to exhibit considerable antitumor activity, particularly against human colon, lung, prostate, ovarian and breast xenografts growing in immunodeficient mice (2, 3) . In addition, the toxicity of LY573636 has been evaluated in vitro and in vivo in different species including rats and beagle dogs (LRL, unpublished data). Currently, a phase I study of LY573636 has been completed, with bone marrow suppression, most commonly thrombocytopenia, identified as the dose-limiting toxicity. Phase II studies in non-small cell lung cancer, malignant metastatic melanoma, ovarian cancer and soft tissue sarcoma are currently in progress (4) . Importantly, the National Cancer Institute's COMPARE analysis did not identify any similarities between LY573636 and any known cytotoxic compound suggesting a unique mechanism of action. These findings are consistent with recent pre-clinical mechanism of action studies indicating that LY573636-induced apoptosis occurs by a mitochondrialtargeted mechanism (LRL, unpublished data). To date, no one has evaluated the effects of LY573636 against malignant hematopoietic cells; in this study, we examined the antileukemic and anti-lymphoma activity of the compound using a large variety of cell lines. ROS determination. Cells were incubated with 40 μM of LY573636 for either 24, 48 or 72 h at 37˚C. They were washed once with complete media, incubated for 30 min at 37˚C with 10 μM of DCFDA (2',7' dichlorofluorescein diacetate) (Sigma-Aldrich) in complete media and analyses were immediately performed by flow cytometry (FACScan).
Materials and methods

Cell
Study of differentiation.
Cells were incubated with various concentrations of LY573636 for four days at 37˚C. Cells were washed with phosphate-buffered saline (PBS) and incubated for 30 min with either R phycoerythrin (RPE)-conjugated murine anti-human CD11b or negative control RPE conjugated murine IgG1 antibody (Dako, Carpinteria, CA). The expression of cell surface antigens was determined by flow cytometry (FACScan).
Results
To determine if LY573636 inhibits the proliferation of malignant hematopoietic cells, different cell lines were cultured in various concentrations of LY573636 (0.5-40 μM) for 96 h and growth inhibition was measured by MTT. The mean ± SD of duplicate experiments performed in triplicate were plotted and the concentration inhibiting 50% of growth (ED 50 ) was calculated (Table I , with representative dose- Mantle cell lymphoma 13
Cells were cultured for 96 h with varying concentrations of LY573636 (0.5-40 μM) and cell growth was measured by MTT assay. Data were plotted and the effective dose, which inhibited 50% of growth (ED 50 ) was calculated for each cell line. Results represent the mean ED 50 of duplicate experiments done with triplicate wells per point.
response curves in Fig. 1 ). In agreement with the antiproliferative effects observed in the solid tumors (LRL, unpublished data), our results demonstrate that LY573636 interfered with the growth potential of a wide panel of human malignant hematopoietic cell lines, including AML (ED 50 , 7 and >40 μM for HL60 and U937 cells, respectively), B-ALL (mean ED 50 , 13 μM), as well as Burkitt's lymphoma, diffuse large B-cell lymphomas and mantle cell lymphomas (mean ED 50 , 21 μM) ( Table I) . Following this initial screen, we chose to limit the remainder of our studies to a few select cell lines from each subtype: two AML cell lines (HL60 and U937) with disparate ED 50 's, as well as Reh (B-ALL), MD901 (diffuse large B-cell lymphoma) and Jeko1 (mantle cell lymphoma) (Fig. 1) .
Previous results demonstrated that LY573636 induced apoptosis in colorectal and ovarian cancer and melanoma cell lines (LRL, unpublished data). To assess whether the antiproliferative effects of LY573636 observed by MTT assay were attributed to an induction of cell death, HL60, U937, Reh, MD901 and Jeko1 cells were cultured in 40 μM of LY573636 or control for 24, 48 and 72 h. While no significant effects were evident after 24 and 48 h (data not shown), HL60, Reh and MD901 cells demonstrated between 3.3-to 4.5-fold increase in the percentage of Annexin V-and PI-double positive cells following a 72-h incubation period. Nevertheless, none of the cell lines exhibited >10% apoptotic cells (Table II) . U937 cells, which were the least sensitive to the growth inhibitory action of LY573636 (Fig. 1, as measured by MTT) , still showed an almost 3-fold increase in apoptotic cells in the presence of LY573636 compared to diluent control cells. In contrast, Jeko1 cells did not exhibit any significant induction of apoptosis.
Mitochondrial membrane permeability and the consequential collapse of the electrochemical potential across the mitochondrial membrane are early key steps in the induction of apoptosis and occur through the formation of membrane pores via the activation of pro-apoptotic proteins and release of cytochrome-C into the cytoplasm (8). LY573636-induced apoptosis in solid tumor cell lines was found to be mediated by the intrinsic, mitochondrial-mediated cell death pathways, associated with a reduction in cellular ATP levels (LRL, unpublished data). To determine whether this mechanism also applied to hematopoietic malignant cell lines used in this study, we looked for changes in mitochondrial membrane potential as a function of mitochondrial damage using the JC-1 dye. In healthy cells, positively charged JC-1 molecules accumulate in aggregates within the negatively charged mitochondria and emit red fluorescence at the 590 nm spectrum. In apoptotic cells, however, the collapse of the mitochondrial membrane potential interferes with the accumulation of the JC-1 molecules, which remain in the cytoplasm in a monomeric form, emitting green fluorescence at the 527 nm spectrum. Hence, healthy cells can easily be HL60  3  10  U937  2  6  MD901  3  10  Reh  2  9  Jeko1  2 
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a Cells were cultured for 72 h with 40 μM of LY573636 and the percentage of Annexin V-and PI-double positive cells was determined by flow cytometry. Data represent the mean of triplicate dishes.
for 72 h (time point at which the induction of apoptosis was observed) and changes in the levels of monomeric JC-1 (green fluorescence) were assessed (Fig. 2) . In HL60, Reh and MD901 cells, a dose-dependent increase in green fluorescence, corresponding to a decrease in mitochondrial membrane potential was observed following treatment with LY573636. HL60 cells demonstrated a mean 6.6-fold increase in green fluorescence compared to the control cells ( Fig. 2A) , while Reh and MD901 exhibited a mean 77-and 81-fold increase, respectively, after culture with 40 μM of LY573636 (Fig. 2C (Fig. 2B) . Remarkably, although Jeko1 cells did not reveal a significant increase in the percentage of cells undergoing apoptosis, they did, however, demonstrate a 15-fold increase in their levels of green fluorescence (Fig. 2E) .
The generation of significant levels of reactive oxygen species (ROS) in a cell occurs as a late event in the induction of apoptosis after the activation of caspases (8) . Given our observations of enhanced apoptosis, coupled with the loss of mitochondrial membrane potential in various cell lines, we assessed the levels of ROS production after exposure to LY573636. Following treatment with LY573636 (40 μM; 24, 48, or 72 h), HL60, U937, Reh, MD901 and Jeko1 cells were incubated with DCFDA, which generates fluorescent diclorofluorescein upon oxidation. We observed a significant time-dependent increase in levels of ROS production (measured by relative DCFDA mean fluorescence) in HL60, Reh and Jeko1 cells (>10-fold) (Fig. 3A, C and E) . The MD901 cells generated an ~3-fold rise in ROS levels after 72 h of treatment (Fig. 3D) . Once again, the least sensitive cell line, U937, did not have a significant enhancement in DCFDA fluorescence, with relative levels comparable to the control even after 72 h of exposure (Fig. 3B) . This is consistent with previous findings in HCT116 colon cancer cells that showed a dose-dependent, congruent induction of apoptosis and ROS upon LY573636 treatment (LRL, unpublished data).
Since the induction of differentiation represents a potential therapeutic strategy in AML, we investigated the ability of LY573636 to induce myeloid differentiation. Myeloid leukemic cells, such as HL60 and U937 used in this study, express specific cell surface antigens as they undergo differentiation (9) . Accordingly, we evaluated by flow cytometry the ability of LY573636 to induce differentiation as measured by the expression of the monocyte-and granulocyte-marker, CD11b. Following a 4-day exposure to a non-apoptotic dose of LY573636 (20 μM), HL60 and U937 exhibited a dose-dependent increase in the percentage of CD11b expressing cells, with >40% and 20% of the cells becoming positive, respectively (Fig. 4) .
Discussion
Acyl sulfonamides, such as LY573636, were initially recognized for their significant antiproliferative activities in solid tumor cell lines, though their mechanism of action was unknown (1) . Subsequent studies have revealed that LY573636 induces apoptosis via a mitochondrial-mediated mechanism, which appears unique among other anti-cancer compounds. However, little is known of the effects of LY573636 on hematopoietic malignancies, which prompted our study of these cells.
Consistent with findings in solid tumors (LRL, unpublished data), the antiproliferative effects of LY573636 observed in our studies demonstrate that LY573636 inhibits growth and induces apoptosis in diverse human malignant hematopoietic cell lines. In most cell lines, a dose-dependent decrease of membrane potential and elevated levels of ROS upon treatment of sensitive cell lines was associated with apoptosis. Importantly, these effects were achieved at LY573636 concentrations that ranged clearly below the maximum tolerated targeted Cmax concentration in patients (420 μg/ml or 960 μM) identified in the phase I study JZAA and taken forward into Phase II (4) .
Notably, apoptosis rates upon a 72-h treatment with LY573636 did not exceed 10% of the cells, though this still demonstrates 3-to 4.5-fold increase of apoptotic cells. Compared to the 8-fold increase in HCT-116 colon cancer cells upon treatment with lower concentrations of LY573636 (LRL, unpublished data), the hematopoietic cells seem to be less sensitive to this compound. Nevertheless, LY57636 alone or in combination might be useful as a therapy for leukemia or lymphoma given the relatively long half-life in humans (~11 days), which can provide prolonged exposure to potentially active drug concentrations (4) (LRL, unpublished data). Furthermore, the compound appears to have a novel mechanism of action supporting the further exploration of LY573636 as a therapeutic agent for acute leukemias and lymphomas. 
